CLEC10A

Across TCGA pan-cancer cohorts, CLEC10A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLEC10A data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher CLEC10A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLEC10A expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

PRAD, STAD, and COAD are the cancer types where CLEC10A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	DFS	Median	All	0.211	0.709	.015	6	view →
COAD	DFS	Median	All	0.160	0.693	.020	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	1.000	0.623	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLEC10A–PRAD (DFS)

Open the PRAD breakdown →